This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Spitz, M. R. Articles by Mills, G. Search for Related Content PubMed PubMed Citation Articles by Spitz, M. R. Articles by Mills, G. Social Bookmarking                            What's this?

Integrative Epidemiology: From Risk Assessment to Outcome Prediction

Margaret R. Spitz, Xifeng Wu, Gordon Mills

From the Departments of Epidemiology and Molecular Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Address reprint requests to Margaret R. Spitz, MD, Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd. Box 189, Houston, TX 77030; e-mail: mspitz{at}mdanderson.org.

In this paper, we advance the concept of integrative epidemiology. Our unifying premise is that the same genes that are implicated in cancer risk may also be involved in a person's propensity to carcinogenic exposure and/or to modulation of therapeutic outcome. In the coming years, molecular epidemiology will play an increasingly prominent role in early detection of cancer and in identifying genetically high-risk subgroups that might benefit disproportionately from more intensive screening or chemoprevention interventions. Molecular epidemiology is also integral to pharmacogenetic research, by constructing genetic profiles that could be used to individualize therapy and to understand the functional consequences of chemoprevention, chemotherapy, or radiotherapy response. At the level of risk assessment, the focus might be on germline polymorphisms in candidate genes; for early detection, epigenetic events in these same or other genes may be relevant; and tumor tissue expression levels, loss of heterozygosity, genomic amplification, rearrangements, or somatic mutations in the same classes of genes may determine outcome. We will provide examples of how changes in the function of a single gene can contribute to susceptibility to carcinogenic exposure, predisposition to cancer development, patient prognosis, and prediction of outcome.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Savas and G. Liu Studying Genetic Variations in Cancer Prognosis (and Risk): A Primer for Clinicians Oncologist, July 1, 2009; 14(7): 657 - 666. [Abstract] [Full Text] [PDF]

				O. I. Olopade, T. A. Grushko, R. Nanda, and D. Huo Advances in Breast Cancer: Pathways to Personalized Medicine Clin. Cancer Res., December 15, 2008; 14(24): 7988 - 7999. [Abstract] [Full Text] [PDF]

				J. McGrath Dissecting the Heterogeneity of Schizophrenia Outcomes Schizophr Bull, March 1, 2008; 34(2): 247 - 248. [Full Text] [PDF]

				P. A. Bradbury, R. S. Heist, M. H. Kulke, W. Zhou, A. L. Marshall, D. P. Miller, L. Su, S. Park, J. Temel, P. Fidias, et al. A Rapid Outcomes Ascertainment System Improves the Quality of Prognostic and Pharmacogenetic Outcomes from Observational Studies Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 204 - 211. [Abstract] [Full Text] [PDF]

				A. L. Hong, D. Huo, H.-J. Kim, Q. Niu, D. L. Fackenthal, S. A. Cummings, E. M. John, D. W. West, A. S. Whittemore, S. Das, et al. UDP-Glucuronosyltransferase 1A1 Gene Polymorphisms and Total Bilirubin Levels in an Ethnically Diverse Cohort of Women Drug Metab. Dispos., August 1, 2007; 35(8): 1254 - 1261. [Abstract] [Full Text] [PDF]

				N. E. Caporaso Integrative Study Designs--Next Step in the Evolution of Molecular Epidemiology? Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 365 - 366. [Full Text] [PDF]

				R. S. Huang, E. O. Kistner, W. K. Bleibel, S. J. Shukla, and M. E. Dolan Effect of population and gender on chemotherapeutic agent-induced cytotoxicity Mol. Cancer Ther., January 1, 2007; 6(1): 31 - 36. [Abstract] [Full Text] [PDF]

				M. Wrensch, K. T. Kelsey, M. Liu, R. Miike, M. Moghadassi, J. D. Sison, K. Aldape, A. McMillan, J. Wiemels, and J. K. Wiencke ERCC1 and ERCC2 polymorphisms and adult glioma Neuro-oncol, October 1, 2005; 7(4): 495 - 507. [Abstract] [PDF]